The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2022 | Long-term follow-up of the TOURMALINE-MM1 trial
In this video, Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, shares some insights into the long-term follow-up of the TOURMALINE-MM1 trial (NCT01564537) evaluating the safety and efficacy of ixazomib, lenalidomide, and dexamethasone for the treatment of relapsed/refractory (R/R) myeloma. Dr Richardson comments on some results from this trial and further explains the importance of interpreting overall survival data appropriately. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
